A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol
作者
Klaus Friedrich Rabe,Fernando J. Martínez,Gary T. Ferguson,Chen Wang,Dave Singh,Jadwiga Anna Wedzicha,Roopa Trivedi,Earl St. Rose,Shaila Ballal,Julie McLaren,Patrick F. Darken,Colin Reisner,Paul Dorinsky